Clinical Trial Update: A Non-Blinded Study Demonstrating the Effectiveness and Safety of Azilect Alone or in Combination Therapy in Parkinson's Disease [Phase 4]

View source ↗

Summary

Phase 4 clinical trial update showing rasagiline (Azilect) alone or in combination is effective and safe in Parkinson's disease.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Drugs mentioned

• Azilect (rasagiline)

Snippet

Sponsor: Teva Neuroscience, Inc. | Conditions: Parkinson's Disease | Phase 4 | Status: COMPLETED